Cangene anthrax antibody product HHS contract extended

Biopharmaceutical company Cangene has extended its existing contract with the U.S. Department of Health and Human Services and signed a new contract with the CDC.

The modified HHS contract concerns the company's development and supply of Anthrax Immune Globulin Intravenous, which is a hyperimmune antibody product developed to treat inhalation anthrax, Contract Research Reports.

The modification, which extends to 2016, Cangene will conduct additional activities to support the obtaining of licensure for AIGIV. The extension is expected to generate as much as $16.5 million in additional revenue for Cangene over the next four years.

"Cangene will continue to pursue opportunities to leverage our core competencies in biodefence while maintaining a focus on our commercial product business and expanding our pipeline," Cangene CEO and President John Sedor said, according to Contract Research.

Under the new Centers for Disease Control and Prevention contract, Cangene will provide Vaccinia Immune Globulin Intravenous to the U.S. Strategic National Stockpile. The company will also provide licensure maintenance activity support services for the product.

The CDC contract is valued at approximately $9.8 million in additional revenue for Cangene during an 18 month period, Contract Research reports.

Vaccinia Immune Globulin Intravenous is a hyperimmune product meant for the treatment and prevention of certain types of severe smallpox vaccination complications. It is considered to be an important smallpox vaccination program component.